From stoutepf@chemsci1.dmpc.com Tue Mar 14 15:13:56 1995 Received: from gatekeeper.es.dupont.com for stoutepf@chemsci1.dmpc.com by www.ccl.net (8.6.10/930601.1506) id OAA13430; Tue, 14 Mar 1995 14:21:58 -0500 Received: by gatekeeper.es.dupont.com; id AA01153; Tue, 14 Mar 95 14:21:50 -0500 Received: from [158.117.153.76] (esm153076.dmpc.com) by chemsci1.dmpc.com (4.1/SMI-4.1) id AA20865; Tue, 14 Mar 95 14:20:21 EST Message-Id: Mime-Version: 1.0 Content-Type: text/plain; charset="us-ascii" X-Organization: The DuPont Merck Pharmaceutical Company X-Mailer: Eudora 1.5.1 for Macintosh Date: Tue, 14 Mar 1995 14:22:56 -0500 To: chemistry@ccl.net From: stoutepf@chemsci1.dmpc.com (Pieter Stouten) Subject: Re: CCL:Spelling question Cc: shenkin@still3.chem.columbia.edu Peter Shenkin wrote: >His name was "van der Waals". > True, BUT when used standalone (e.g. without a first name) the "v" in "van" gets capitalized. So "Van der Waals" is correct. Cheers, Pieter. -- DuPont Merck is getting its own computer network (physically separated -- from Du Pont) and we are having intermittent e-mail problems. If mail to -- me bounces, please try again some hours later. Sorry for any inconvenience. Pieter Stouten, Senior Research Scientist Computer Aided Drug Design Group The DuPont Merck Pharmaceutical Company P.O. Box 80353, Wilmington, DE 19880-0353 Phone: +1 (302) 695 3515 Fax: +1 (302) 695 2813 Internet: stoutepf@chemsci1.dmpc.com CompuServe: 73172,2004 WWW: http://www.halcyon.com/stouten/stouten.html